Clinical Trials

Inclusion Criteria:

- Provide signed and dated informed consent form

- Willing to comply with all study procedures and be available for the duration of the
study

- At least 21 years old

- Be diagnosed with breast cancer (T1 or greater LABC, any N and M0)

- Be scheduled for neoadjuvant chemotherapy

- Be medically stable

- Be conscious and able to comply with study procedures

- If a female of child-bearing potential, must have a negative urine pregnancy test

Exclusion Criteria:

- Females who are pregnant or nursing

- Patients with other primary cancers requiring systemic treatment

- Patients with any distal metastatic disease

- Patients undergoing neoadjuvant endocrine therapy

- Patients who are medically unstable, patients who are seriously or terminally ill, and
patients whose clinical course is unpredictable. For example:

- Patients on life support or in a critical care unit;

- Patients with unstable occlusive disease (e.g., crescendo angina);

- Patients with clinically unstable cardiac arrhythmias, such as recurrent
ventricular tachycardia;

- Patients with uncontrolled congestive heart failure (New York Heart Association
[NYHA] Class IV);

- Patients with recent cerebral hemorrhage;

- Patients who have undergone surgery within 24 hours prior to the study
sonographic examination

- Patients with known hypersensitivity or allergy to any component of Definity

- Patients with unstable cardiopulmonary conditions or respiratory distress syndrome

- Patients with uncontrollable emphysema, pulmonary vasculitis, pulmonary hypertension
or a history of pulmonary emboli

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 3/6/2024. Questions regarding updates should be directed to the study team contact.